BB102 not checked

Broadenbio Ltd., Co.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Hepatocellular Carcinoma (HCC), Advanced Solid Tumor
Main trialPhase 2
“This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma. This study has two phase: dose escalation phase and expansion phase.”In the company’s words, NCT07239986 on ClinicalTrials.gov

Other drugs for Hepatocellular Carcinoma (HCC)

All 130 drugs for Hepatocellular Carcinoma (HCC)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Jun 2027 A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
Phase 1Recruiting Dec 2026 A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BB102

Following is part of Solo: you see every change to BB102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in